List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1175832/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. European Heart Journal, 2022, 43, 1428-1431.	2.2	10
2	Global representation of heart failure clinical trial leaders, collaborators, and enrolled participants: a bibliometric review 2000–20. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 659-669.	4.0	13
3	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASISâ€HF</scp> and <scp>RALES</scp> . European Journal of Heart Failure, 2022, 24, 529-538.	7.1	7
4	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	1.0	2
5	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. Clinical Research in Cardiology, 2022, 111, 451-459.	3.3	6
6	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 35-45.	11.4	29
7	Aspirin use is associated with increased risk for incident heart failure: a patientâ€level pooled analysis. ESC Heart Failure, 2022, 9, 685-694.	3.1	10
8	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	7.1	16
9	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
10	Early benefit with empagliflozin in heart failure with preserved ejection fraction: <scp>insights from the EMPERORâ€Preserved trial</scp> . European Journal of Heart Failure, 2022, 24, 245-248.	7.1	26
11	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350.	2.9	81
12	<scp>Angiotensin–neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	7.1	14
13	Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas. International Journal of Cardiology, 2022, 352, 78-83.	1.7	2
14	A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. American Heart Journal, 2022, 247, 76-89.	2.7	12
15	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424.	2.2	144
16	Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008685.	3.9	39
17	Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation, 2022, 145, 1205-1217.	1.6	50
18	Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness. European Heart Journal Open, 2022, 2, .	2.3	6

#	Article	IF	CITATIONS
19	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	7.1	7
20	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923.	3.3	10
21	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 2212-2220.	2.2	10
22	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With HeartÂFailure and Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137.	2.8	36
23	Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort. Atherosclerosis, 2022, 346, 1-9.	0.8	6
24	Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk. CKJ: Clinical Kidney Journal, 2022, 15, 822-824.	2.9	2
25	Patient partnership in cardiovascular clinical trials. European Heart Journal, 2022, 43, 1432-1437.	2.2	4
26	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	2.2	8
27	High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. European Journal of Preventive Cardiology, 2022, 29, 1731-1739.	1.8	3
28	Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20â€Year Followâ€Up. Journal of the American Heart Association, 2022, 11, e023301.	3.7	1
29	HF-567-01 THE BENEFIT OF AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN HEART FAILURE PATIENTS TREATED WITH EMPAGLIFLOZIN: AN ANALYSIS FROM THE EMPEROR-REDUCED TRIAL. Heart Rhythm, 2022, 19, S72-S73.	0.7	0
30	Outcomes with empagliflozin in heart failure with preserved ejection fraction using <scp>DELIVER</scp> â€like endpoint definitions. European Journal of Heart Failure, 2022, 24, 1400-1405.	7.1	14
31	Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal, 2022, 43, 2984-2993.	2.2	30
32	Incorporating Cultural Competence and Cultural Humility in Cardiovascular Clinical Trials to Increase Diversity Among Participants. Journal of the American College of Cardiology, 2022, 80, 89-92.	2.8	7
33	Biomarkerâ€driven prognostic models in chronic heart failure with preserved ejection fraction: the <scp>EMPEROR</scp> –Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878.	7.1	21
34	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446.	2.2	39
35	Empagliflozin Improves Outcomes inÂPatients With HeartÂFailure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	2.8	21
36	Heritability of a resting heart rate in a 20-year follow-up family cohort with GWAS data: Insights from the STANISLAS cohort. European Journal of Preventive Cardiology, 2021, 28, 1334-1341.	1.8	12

#	Article	IF	CITATIONS
37	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. European Journal of Heart Failure, 2021, 23, 703-712.	7.1	87
38	Plasma <scp>D</scp> â€dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the <scp>COMMANDERâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 648-656.	7.1	13
39	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236.	3.8	8
40	Heart failure treatment upâ€ŧitration and outcome and age: an analysis of BIOSTAT HF. European Journal of Heart Failure, 2021, 23, 436-444.	7.1	20
41	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. European Journal of Internal Medicine, 2021, 85, 41-49.	2.2	11
42	Cardiac implantable electronic device-detected atrial fibrillation—"To anticoagulate or not to anticoagulate, that is the question― The noble or ignoble choice?. Heart Rhythm, 2021, 18, 347-348.	0.7	0
43	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. Heart Failure Reviews, 2021, 26, 255-262.	3.9	0
44	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336.	1.6	222
45	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation, 2021, 143, 310-321.	1.6	168
46	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. Journal of Cardiac Failure, 2021, 27, 233-241.	1.7	17
47	Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (<scp>TRSâ€HF_{DM}</scp>) in patients in the <scp>ACCORD</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 782-790.	4.4	19
48	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	27.0	381
49	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
50	The Future of Meat: Health Impact Assessment with Randomized Evidence. American Journal of Medicine, 2021, 134, 569-575.	1.5	9
51	Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€CHF. European Journal of Heart Failure, 2021, 23, 43-57.	7.1	19
52	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. American Journal of Medicine, 2021, 134, 166-175.	1.5	11
53	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 297-308.	1.7	4
54	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European Heart Journal, 2021, 42, 152-161.	2.2	249

#	Article	IF	CITATIONS
55	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. Heart Failure Reviews, 2021, 26, 11-21.	3.9	1
56	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology—Cardiovascular Round Table. Cardiovascular Research, 2021, 117, 1248-1256.	3.8	11
57	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 671-680.	2.2	96
58	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	2.2	114
59	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal, 2021, 42, 4887-4890.	2.2	11
60	Impact of Anti-hypertensive Therapy in the Sexual Health of Men and Women: An Analysis From the SPRINT Trial. American Journal of Hypertension, 2021, 34, 760-772.	2.0	1
61	Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction. ESC Heart Failure, 2021, 8, 1700-1705.	3.1	8
62	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 546-556.	2.7	26
63	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784.	7.1	12
64	Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPAâ€REG OUTCOME Trial. Journal of the American Heart Association, 2021, 10, e020053.	3.7	9
65	Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. ESC Heart Failure, 2021, 8, 1827-1839.	3.1	15
66	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1580-1587.	4.4	16
67	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958.	1.6	15
68	Empagliflozin in Patients With HeartÂFailure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology, 2021, 77, 1381-1392.	2.8	94
69	The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567.	7.3	15
70	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 983-991.	7.1	70
71	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	2.2	29
72	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. European Journal of Heart Failure, 2021, 23, 567-577.	7.1	26

#	Article	IF	CITATIONS
73	Blood pressure reduction and antiâ€hypertensive treatment choice: A postâ€hoc analysis of the <scp>SPRINT</scp> trial. Clinical Cardiology, 2021, 44, 665-674.	1.8	3
74	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	2.7	47
75	The struggle towards a Universal Definition of Heart Failure—how to proceed?. European Heart Journal, 2021, 42, 2331-2343.	2.2	55
76	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	3.9	25
77	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	4
78	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	4.1	46
79	Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). American Journal of Cardiology, 2021, 146, 15-21.	1.6	8
80	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. Clinical Cardiology, 2021, 44, 780-788.	1.8	3
81	Nonâ€adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatographyâ€ŧandem mass spectrometry (results of a prospective) Tj ETQq1 1 0.78	431 741 rgBT	/O ve rlock 10
82	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	7.1	37
83	Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: Results from the NAtional TUnisian REgistry of Heart Failure (NATURE-HF). PLoS ONE, 2021, 16, e0251658.	2.5	11
84	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.5	47
85	Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity. The Lancet Healthy Longevity, 2021, 2, e371-e379.	4.6	5
86	What can heart failure trialists learn from oncology trialists?. European Heart Journal, 2021, 42, 2373-2383.	2.2	9
87	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Circulation: Heart Failure, 2021, 14, e008075.	3.9	3
88	Association between upâ€ŧitration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	7.1	11
89	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	7.1	9
90	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	2.2	38

#	Article	IF	CITATIONS
91	Concentrationâ€dependent clinical and prognostic importance of highâ€sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <scp>EMPEROR</scp> â€Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	7.1	30
92	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. Journal of the American College of Cardiology, 2021, 77, 2960-2972.	2.8	45
93	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction. International Journal of Cardiology, 2021, 332, 35-37.	1.7	4
94	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	3.1	11
95	Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial. BMJ Open Diabetes Research and Care, 2021, 9, e002408.	2.8	1
96	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
97	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 2021, 20, 163.	6.8	7
98	Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials. Circulation, 2021, 144, 1193-1195.	1.6	34
99	Effect of patientâ€centered transitional care services on patientâ€reported outcomes in heart failure: sexâ€specific analysis of the <scp>PACTâ€HF</scp> randomized controlled trial. European Journal of Heart Failure, 2021, 23, 1488-1498.	7.1	22
100	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195
101	Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTAT HF</scp> . European Journal of Heart Failure, 2021, 23, 1750-1758.	7.1	32
102	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	1.7	14
103	Empagliflozin and Major Renal Outcomes in Heart Failure. New England Journal of Medicine, 2021, 385, 1531-1533.	27.0	78
104	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
105	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464.	2.2	33
106	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPERORâ€Preserved</scp> trial. European Journal of Heart Failure, 2021, 23, 1798-1799.	7.1	21
107	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e022069.	3.7	15
108	Prognostic Importance of NT-proBNP andÂEffect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	2.8	55

#	Article	IF	CITATIONS
109	Empagliflozin Improves Cardiovascular and Renal Outcomes in HeartÂFailure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348.	2.8	52
110	Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort. Clinical Cardiology, 2021, 44, 1516-1525.	1.8	7
111	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021, 240, 73-80.	2.7	1
112	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€~OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	2.2	77
113	The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. European Journal of Heart Failure, 2021, 23, 1831-1840.	7.1	14
114	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 127-131.	1.0	3
115	Design and Rationale of the National Tunisian Registry of Heart Failure (NATURE-HF): Protocol for a Multicenter Registry Study. JMIR Research Protocols, 2021, 10, e12262.	1.0	3
116	OUP accepted manuscript. European Heart Journal, 2021, , .	2.2	0
117	Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis. Frontiers in Cardiovascular Medicine, 2021, 8, 754784.	2.4	6
118	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. European Journal of Heart Failure, 2021, , .	7.1	5
119	No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. Archives of Cardiovascular Diseases, 2021, 114, 814-817.	1.6	2
120	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , .	1.7	3
121	Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial. CKJ: Clinical Kidney Journal, 2020, 13, 116-122.	2.9	24
122	Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study. International Journal of Cardiology, 2020, 299, 192-198.	1.7	14
123	Plasma proteomic approach in patients withÂheart failure: insights into pathogenesis ofÂdisease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80.	7.1	28
124	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. European Journal of Internal Medicine, 2020, 71, 62-69.	2.2	12
125	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. European Journal of Heart Failure, 2020, 22, 1147-1155.	7.1	50
126	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	12.8	466

#	Article	IF	CITATIONS
127	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. Journal of the American Heart Association, 2020, 9, e012797.	3.7	28
128	Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a postâ€hoc analysis of the Aldoâ€DHF trial. European Journal of Heart Failure, 2020, 22, 559-561.	7.1	0
129	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 2020, 22, 1402-1411.	7.1	19
130	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
131	Postâ€discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. European Journal of Heart Failure, 2020, 22, 164-167.	7.1	3
132	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	2.7	61
133	Cardiovascular and nonâ€cardiovascular death distinction: the utility of troponin beyond Nâ€terminal proâ€Bâ€type natriuretic peptide. Findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2020, 22, 81-89.	7.1	15
134	Estimating the Lifetime Benefits of Treatments for HeartÂFailure. JACC: Heart Failure, 2020, 8, 984-995.	4.1	15
135	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
136	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 435-450.	2.8	7
137	Design of a prospective patientâ€level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398.	7.1	19
138	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	7.1	93
139	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. Theranostics, 2020, 10, 8665-8676.	10.0	18
140	Acute myocardial infarction and acute heart failure in the Middle East and North Africa: Study design and pilot phase study results from the PEACE MENA registry. PLoS ONE, 2020, 15, e0236292.	2.5	9
141	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology, 2020, 76, 503-514.	2.8	77
142	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. American Heart Journal, 2020, 229, 40-51.	2.7	4
143	Ten lessons from the <scp>EMPERORâ€Reduced</scp> trial. European Journal of Heart Failure, 2020, 22, 1991-1993.	7.1	6
144	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821

#	Article	IF	CITATIONS
145	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829.	13.7	816
146	Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal, 2020, 41, 3398-3401.	2.2	20
147	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
148	Serum potassium in the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2020, 22, 2056-2064.	7.1	34
149	VERTIS-CV. Circulation, 2020, 142, 2216-2218.	1.6	4
150	Reduced Diuretic Dose in Patients Treated With Eplerenone. Circulation: Heart Failure, 2020, 13, e006597.	3.9	11
151	Empagliflozin for Patients With Presumed Resistant Hypertension: A <i>Post Hoc</i> Analysis of the EMPA-REG OUTCOME Trial. American Journal of Hypertension, 2020, 33, 1092-1101.	2.0	23
152	Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study. PLoS ONE, 2020, 15, e0232572.	2.5	3
153	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nature Reviews Cardiology, 2020, 17, 641-655.	13.7	143
154	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. European Journal of Heart Failure, 2020, 22, 1615-1624.	7.1	24
155	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
156	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. American Journal of Kidney Diseases, 2020, 76, 109-120.	1.9	10
157	Abnormalities of Potassium in HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 2836-2850.	2.8	94
158	Systolic Blood Pressure in HeartÂFailure With Preserved Ejection Fraction TreatedÂWith Sacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 75, 1644-1656.	2.8	46
159	Hypo―and hyperkalaemia in heart failure. Navigating between Scylla and Charybdis. European Journal of Heart Failure, 2020, 22, 1399-1401.	7.1	0
160	Association of Dietary Patterns Derived Using Reducedâ€Rank Regression With Subclinical Cardiovascular Damage According to Generation and Sex in the STANISLAS Cohort. Journal of the American Heart Association, 2020, 9, e013836.	3.7	9
161	PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middleâ€Aged Population: The STANISLAS Cohort. Journal of the American Heart Association, 2020, 9, e014758. 	3.7	15
162	Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 2020, 109, 1358-1365.	3.3	11

#	Article	IF	CITATIONS
163	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Failure, 2020, 7, 953-963.	3.1	9
164	Baroreflex Activation Therapy in Patients With HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 1-13.	2.8	121
165	Effects of combined renin–angiotensin–aldosterone system inhibitor and betaâ€blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTATâ€CHF</scp> and <scp>ASIANâ€HF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482.	7.1	24
166	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. European Heart Journal, 2020, 41, 1673-1683.	2.2	39
167	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 1761-1769.	0.7	5
168	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
169	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure, 2020, 22, 834-844.	7.1	36
170	Predictors of sudden cardiac death in highâ€risk patients following a myocardial infarction. European Journal of Heart Failure, 2020, 22, 848-855.	7.1	14
171	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€oncept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure. 2020. 22. 1711-1723.	7.1	43
172	Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVEâ€HF trial. ESC Heart Failure, 2020, 7, 503-511.	3.1	12
173	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977.	3.3	7
174	Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients. European Journal of Heart Failure, 2020, 22, 1907-1911.	7.1	6
175	Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure postâ€discharge. ESC Heart Failure, 2020, 7, 1257-1263.	3.1	9
176	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. ESC Heart Failure, 2020, 7, 996-1006.	3.1	10
177	A network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâ€ischaemic heart failure. European Journal of Heart Failure, 2020, 22, 821-833.	7.1	28
178	Eplerenone prevents an increase in serum carboxyâ€ŧerminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. European Journal of Heart Failure, 2020, 22, 901-903.	7.1	8
179	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.6	2
180	Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up. American Journal of Hypertension, 2020, 33, 869-878.	2.0	16

#	Article	IF	CITATIONS
181	Use of the Win Ratio in Cardiovascular Trials. JACC: Heart Failure, 2020, 8, 441-450.	4.1	34
182	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.	13.7	376
183	Diagnostic performance of congestion score index evaluated from chest radiography for acute heart failure in the emergency department: A retrospective analysis from the PARADISE cohort. PLoS Medicine, 2020, 17, e1003419.	8.4	10
184	Circulating plasma proteins and new-onset diabetes in a population-based study: proteomic and genomic insights from the STANISLAS cohort. European Journal of Endocrinology, 2020, 183, 285-295.	3.7	7
185	Reproducibility in Echotracking Assessment of Local Carotid Stiffness, Diameter and Thickness in a Population-based Study (The STANISLAS Cohort Study). Artery Research, 2020, 26, 5-12.	0.6	6
186	Title is missing!. , 2020, 15, e0232572.		0
187	Title is missing!. , 2020, 15, e0232572.		Ο
188	Title is missing!. , 2020, 15, e0232572.		0
189	Title is missing!. , 2020, 15, e0232572.		0
190	Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure. International Journal of Cardiology, 2019, 274, 195-201.	1.7	22
191	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 2019, 105, 307-314.	2.9	28
192	Heart failure around the world. European Journal of Heart Failure, 2019, 21, 1187-1196.	7.1	56
193	Evaluation of the effect of sodium–glucose coâ€ŧransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	7.1	155
194	Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2019, 7, 862-874.	4.1	77
195	Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e005596.	3.9	17
196	Evaluation of the effects of sodium–glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	7.1	205
197	Eplerenone in patients with myocardial infarction and "midâ€range―ejection fraction: An analysis from the EPHESUS trial. Clinical Cardiology, 2019, 42, 1106-1112.	1.8	13
198	Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65

#	ARTICLE	IF	CITATIONS
199	Autonomic Nervous System Modulation in Heart Failure. Circulation: Heart Failure, 2019, 12, e006491.	3.9	4
200	Telomere length tracking in children and their parents: implications for adult onset diseases. FASEB Journal, 2019, 33, 14248-14253.	0.5	42
201	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and nonâ€sudden cardiac death in myocardial infarction survivors with heart failure. European Journal of Heart Failure, 2019, 21, 1248-1258.	7.1	21
202	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263.	13.7	159
203	Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	27.0	1,485
204	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	13.7	512
205	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
206	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 2019, 40, 3593-3602.	2.2	69
207	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circulation: Heart Failure, 2019, 12, e005875.	3.9	38
208	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
209	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. American Heart Journal, 2019, 215, 83-90.	2.7	7
210	Estimated Long-Term Survival With Eplerenone. Journal of the American College of Cardiology, 2019, 73, 2357-2359.	2.8	6
211	The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 965-973.	7.1	172
212	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. JAMA Cardiology, 2019, 4, 515.	6.1	51
213	The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney International, 2019, 95, 747-749.	5.2	22
214	Heart failure drug treatment. Lancet, The, 2019, 393, 1034-1044.	13.7	233
215	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195

Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS) Tj ETQq0 0.0 rgBT /Overlock 10

#	Article	IF	CITATIONS
217	Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. International Journal of Cardiology, 2019, 289, 91-98.	1.7	21
218	Is Sacubitril/Valsartan Antifibrotic?. Journal of the American College of Cardiology, 2019, 73, 807-809.	2.8	7
219	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	4.1	63
220	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 2019, 21, 386-388.	7.1	24
221	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASISâ€HF trial. European Journal of Heart Failure, 2019, 21, 345-351.	7.1	43
222	Renin-angiotensin-aldosterone system and kidney interactions in heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988941.	1.7	6
223	Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 2019, 218, 66-74.	2.7	23
224	MRAs in Elderly HF Patients. JACC: Heart Failure, 2019, 7, 1012-1021.	4.1	33
225	Health-related determinants of undiagnosed arterial hypertension: a population-based study. Family Practice, 2019, 36, 276-283.	1.9	11
226	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal, 2019, 40, 2907-2919.	2.2	32
227	Clinical correlates and outcome associated with changes in 6â€minute walking distance in patients with heart failure: findings from the BIOSTAT HF study. European Journal of Heart Failure, 2019, 21, 218-226.	7.1	25
228	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). American Journal of Cardiology, 2019, 123, 382-391.	1.6	12
229	Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure. Circulation, 2019, 139, 362-365.	1.6	14
230	Echocardiographic diastolic function evolution in patients with an anterior <scp>Q</scp> â€wave myocardial infarction: insights from the <scp>REVE</scp> â€2 study. ESC Heart Failure, 2019, 6, 70-79.	3.1	4
231	Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886.	7.1	68
232	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT HF study. European Journal of Heart Failure, 2019, 21, 112-120.	7.1	44
233	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 231-241.	1.0	22
234	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. European Heart Journal, 2019, 40, 880-886.	2.2	34

#	Article	IF	CITATIONS
235	World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.	2.3	67
236	Assessment of Tunisian acceptance to participate in a Clinical Trial. Tunisie Medicale, 2019, 97, 516-518.	0.2	0
237	The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. European Journal of Heart Failure, 2018, 20, 963-972.	7.1	35
238	Cohort Profile: Rationale and design of the fourth visit of the STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France. International Journal of Epidemiology, 2018, 47, 395-395j.	1.9	33
239	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clinical Cardiology, 2018, 41, 1022-1027.	1.8	5
240	Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a populationâ€based study. European Journal of Heart Failure, 2018, 20, 1066-1068.	7.1	8
241	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq1 1 0.78	8431 .% rgB	T /Qverlock 1
242	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. International Journal of Cardiology, 2018, 254, 215-221.	1.7	19
243	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 398-405.	4.5	28
244	Interpretation of the ATHENA Trial—Caveats and Future Directions. JAMA Cardiology, 2018, 3, 89.	6.1	2
245	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 727-735.	2.8	28
246	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 386-398.	2.8	35
247	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. European Journal of Heart Failure, 2018, 20, 738-747.	7.1	109
248	Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€CHF. European Journal of Heart Failure, 2018, 20, 923-930.	7.1	57
249	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90.	1.7	55
250	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. American Journal of Hypertension, 2018, 31, 407-414.	2.0	26
251	Association between mean systolic and diastolic blood pressure throughout the followâ€up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the Highâ€Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 2018. 20. 323-331.	7.1	23
252	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging. Circulation Research, 2018, 122, 23-25.	4.5	13

#	Article	IF	CITATIONS
253	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. European Heart Journal, 2018, 39, 2793-2799.	2.2	26
254	Highâ€sensitivity <scp>C</scp> â€reactive protein, lowâ€density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the <scp>EXAMINE</scp> (<scp>Examination of) Tj ETQq0 0 0 rgBT</scp>	/Qverlock 4.4	10 Tf 50 70
	Metabolism, 2018, 20, 654-659.		
255	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. Circulation, 2018, 137, 1320-1330.	1.6	121
256	Preâ€discharge and early postâ€discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 281-291.	7.1	33
257	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	3.1	21
258	Mineralocorticoid receptor antagonists in patients with acute myocardial infarction — A systematic review and meta-analysis of randomized trials. American Heart Journal, 2018, 195, 60-69.	2.7	21
259	Rising incidence of heart failure demands action. Lancet, The, 2018, 391, 518-519.	13.7	53
260	Integrative Assessment of Congestion inÂHeart Failure Throughout the PatientÂJourney. JACC: Heart Failure, 2018, 6, 273-285.	4.1	152
261	Nuclear magnetic resonanceâ€based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. European Journal of Heart Failure, 2018, 20, 663-673.	7.1	47
262	Adaptive servoâ€ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVEâ€HF. European Journal of Heart Failure, 2018, 20, 536-544.	7.1	54
263	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 677-686.	7.1	21
264	A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study. Journal of Cardiac Failure, 2018, 24, 811.	1.7	1
265	Hyponatraemia, hyperglycaemia and worsening renal function at first blood sample on emergency department admission as predictors of in-hospital death in patients with dyspnoea with suspected acute heart failure: retrospective observational analysis of the PARADISE cohort. BMJ Open, 2018, 8, e019557.	1.9	10
266	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 1760-1763.	7.1	2
267	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004783.	2.2	13
268	Average Clinicianâ€Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. Journal of the American Heart Association, 2018, 7, e009114.	3.7	19
269	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation, 2018, 138, 1039-1053.	1.6	24
270	Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. International Journal of Cardiology, 2018, 271, 181-185.	1.7	14

#	Article	IF	CITATIONS
271	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	1.7	140
272	Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction. JAMA Internal Medicine, 2018, 178, 920.	5.1	1
273	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine, 2018, 44, 847-856.	8.2	106
274	Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings. European Journal of Heart Failure, 2018, 20, 1300-1302.	7.1	4
275	Waistâ€ŧoâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277.	7.1	85
276	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. International Journal of Cardiology, 2018, 272, 260-266.	1.7	24
277	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	3.9	117
278	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.	3.9	26
279	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the) Tj ETQq1 1 0.78	34314 rgB⁻ 1.6 rgB⁻	[/Qverlock]
280	Reply. JACC: Heart Failure, 2018, 6, 442-443.	4.1	1
281	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. American Heart Journal, 2018, 204, 139-150.	2.7	27
282	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	2.8	199
283	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. New England Journal of Medicine, 2018, 379, 1332-1342.	27.0	265
284	Cardiorenal Syndrome Revisited. Circulation, 2018, 138, 929-944.	1.6	207
285	Antihyperglycemic Therapies to TreatÂPatients With Heart Failure andÂDiabetesÂMellitus. JACC: Heart Failure, 2018, 6, 813-822.	4.1	21
286	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875.	2.2	47
287	Association between abdominal adiposity and 20-year subsequent aortic stiffness in an initially healthy population-based cohort. Journal of Hypertension, 2018, 36, 2077-2084.	0.5	8
288	Cardiovascular Outcomes Reported in Hemodialysis Trials. Journal of the American College of Cardiology, 2018, 71, 2802-2810.	2.8	16

#	Article	IF	CITATIONS
289	The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function. European Journal of Heart Failure, 2017, 19, 603-614.	7.1	27
290	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <scp>T</scp> he <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 664-671.	4.4	53
291	Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation. Hypertension, 2017, 69, 494-500.	2.7	34
292	Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990–2013: findings from the Global Burden of Disease Study 2013. Annals of the Rheumatic Diseases, 2017, 76, 1365-1373.	0.9	81
293	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) Tj ETQq1 1	0.7 &\$ 314	rg B ∓/Overl₀
294	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure, 2017, 19, 627-634.	7.1	183
295	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. Heart Rhythm, 2017, 14, 763-782.	0.7	47
296	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	37
297	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	7.1	280
298	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 962-969.	4.4	26
299	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. European Journal of Heart Failure, 2017, 19, 974-986.	7.1	29
300	A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the Highâ€Risk <scp>MI</scp> Database. European Journal of Heart Failure, 2017, 19, 635-642.	7.1	24
301	Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease. Circulation, 2017, 135, 1769-1771.	1.6	38
302	Risk for Incident Heart Failure: A Subject‣evel Metaâ€Analysis From the Heart "OMics―in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	3.7	41
303	Reproducibility of echocardiographic assessment of 2D-derived longitudinal strain parameters in a population-based study (the STANISLAS Cohort study). International Journal of Cardiovascular Imaging, 2017, 33, 1361-1369.	1.5	24
304	Influence of atrial fibrillation on postâ€discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <scp>ASTRONAUT</scp> trial. European Journal of Heart Failure, 2017, 19, 552-562.	7.1	23
305	Prognostic factors associated with 15-year mortality in patients with hospitalized systolic HF: Results of the observational community-based EPICAL cohort study. International Journal of Cardiology, 2017, 228, 940-947.	1.7	10
306	Impact of Changes in Consensus Diagnostic Recommendations on theÂEchocardiographic Prevalence of DiastolicÂDysfunction. Journal of the American College of Cardiology, 2017, 69, 3119-3121.	2.8	53

#	Article	IF	CITATIONS
307	Monitoring renal safety in mineralocorticoid receptor antagonist trials. European Journal of Heart Failure, 2017, 19, 466-468.	7.1	2
308	MINERALOCORTICOID RECEPTOR ANTAGONISTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. Journal of the American College of Cardiology, 2017, 69, 267.	2.8	0
309	AVERAGE CLINICIAN MEASURED BLOOD PRESSURE PREDICT CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES FOLLOWING ACUTE CORONARY SYNDROMES IN THE EXAMINE TRIAL. Journal of the American College of Cardiology, 2017, 69, 1676.	2.8	1
310	Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Failure Reviews, 2017, 22, 263-277.	3.9	18
311	Lack of Diuretic Efficiency (but Not Low Diuresis) Early in An Acutely Decompensated Heart Failure Episode Is Associated with Increased 180-Day Mortality. CardioRenal Medicine, 2017, 7, 137-149.	1.9	12
312	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	7.1	17
313	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the <scp>EMPHASISâ€HF</scp> trial. European Journal of Heart Failure, 2017, 19, 1186-1197.	7.1	75
314	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. International Journal of Cardiology, 2017, 249, 274-281.	1.7	1
315	Utility of Growth Differentiation Factor-15, AÂMarker of Oxidative Stress and Inflammation, in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 724-734.	4.1	69
316	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
317	The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	2.8	43
318	The potential role and rationale for treatment of heart failure with sodium–glucose coâ€ŧransporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	7.1	139
319	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology, 2017, 2, 1025.	6.1	280
320	Role of Payers in the Development of Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2017, 70, 2822-2830.	2.8	5
321	Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	4.1	238
322	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	27.0	355
323	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. International Journal of Cardiology, 2017, 244, 229-234.	1.7	113
324	Effect of Significant Weight Change on Inappropriate Implantable Cardioverterâ€Defibrillator Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 9-16.	1.2	4

#	Article	IF	CITATIONS
325	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 2017, 19, 792-799.	7.1	34
326	Association of betaâ€blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matchedâ€cohort analysis from the Highâ€Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 2017, 19, 271-279.	7.1	32
327	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. Free Radical Research, 2017, 51, 14-23.	3.3	9
328	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <scp>BIOSTATâ€CHF</scp> . European Journal of Heart Failure, 2017, 19, 1284-1293.	7.1	79
329	Association of Empirically Derived Dietary Patterns with Cardiovascular Risk Factors: A Comparison of PCA and RRR Methods. PLoS ONE, 2016, 11, e0161298.	2.5	30
330	Natriuretic Peptides, 6-Min Walk Test, andÂQuality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. Journal of the American College of Cardiology, 2016, 68, 2690-2707.	2.8	83
331	Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials. Thrombosis Research, 2016, 144, 32-39.	1.7	4
332	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. International Journal of Cardiology, 2016, 216, 46-51.	1.7	20
333	Lung ultrasound: a diagnostic and prognostic tool at every step in the pathway of care for acute heart failure. American Journal of Emergency Medicine, 2016, 34, 656-657.	1.6	7
334	Early Aldosterone Blockade in AcuteÂMyocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 1917-1927.	2.8	86
335	Echocardiography in Hypertension in the Era of Risk Stratification and Personalized Medicine. American Journal of Hypertension, 2016, 29, 792-795.	2.0	3
336	Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation, 2016, 134, 847-857.	1.6	144
337	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	2.8	86
338	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacological Research, 2016, 113, 585-591.	7.1	91
339	A tentative interpretation of the <scp>TOPCAT</scp> trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure, 2016, 18, 1411-1414.	7.1	31
340	Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial). American Journal of Cardiology, 2016, 118, 1442-1447.	1.6	8
341	Globalization of heart failure trials: no turning back on this paradigm. European Heart Journal, 2016, 37, 3175-3177.	2.2	4
342	Health in times of uncertainty in the eastern Mediterranean region, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet Global Health, 2016, 4, e704-e713.	6.3	147

#	Article	IF	CITATIONS
343	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	2.7	21
344	Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis. Lancet Respiratory Medicine,the, 2016, 4, 873-881.	10.7	80
345	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114.	2.2	274
346	Oral Anticoagulant Agents in Patients WithÂAtrial Fibrillation and Heart Failure. JACC: Heart Failure, 2016, 4, 881-884.	4.1	0
347	Roadmap for cardiovascular prevention trials in chronic kidney disease. Lancet, The, 2016, 388, 1964-1966.	13.7	13
348	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrology Dialysis Transplantation, 2016, 33, gfw360.	0.7	14
349	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	4.1	48
350	Intima–Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Populationâ€Based Cohort (STANISLAS Cohort Study). Journal of the American Heart Association, 2016, 5,	3.7	62
351	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. European Heart Journal, 2016, 37, 2455-2464.	2.2	29
352	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 2016, 1, 93-100.	5.5	1
353	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care, 2016, 39, 1267-1273.	8.6	47
354	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the <scp>EMPHASISâ€HF</scp> study. European Journal of Heart Failure, 2016, 18, 1175-1181.	7.1	12
355	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. American Journal of Cardiology, 2016, 117, 1144-1150.	1.6	23
356	Heart failure event definitions in drug trials in patients with type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2016, 4, 294-296.	11.4	26
357	Left-to-right atrial shunting: new hope for heart failure?. Lancet, The, 2016, 387, 1253-1255.	13.7	4
358	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the) Tj ETQq0 0	0 rg <mark>BŢ</mark> /Ον	erlock 10 Tf 5
359	Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial	2.5	46

#	Article	IF	CITATIONS
361	Maintenance of serum potassium with sodium zirconium cyclosilicate (<scp>ZS</scp> â€9) in heart failure patients: results from a phase 3 randomized, doubleâ€blind, placeboâ€controlled trial. European Journal of Heart Failure, 2015, 17, 1050-1056.	7.1	143
362	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASISâ€HF). European Journal of Heart Failure, 2015, 17, 707-716.	7.1	16
363	Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. European Journal of Heart Failure, 2015, 17, 1172-1181.	7.1	208
364	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	7.1	109
365	Geographic differences in heart failure trials. European Journal of Heart Failure, 2015, 17, 893-905.	7.1	64
366	Length of hospital stay and 30â€day readmission following heart failure hospitalization: insights from the <scp>EVEREST</scp> trial. European Journal of Heart Failure, 2015, 17, 1022-1031.	7.1	52
367	Agents with vasodilator properties in acute heart failure: how to design successful trials. European Journal of Heart Failure, 2015, 17, 652-664.	7.1	24
368	Reproducibility in Echocardiographic Assessment of Diastolic Function in a Population Based Study (The STANISLAS Cohort Study). PLoS ONE, 2015, 10, e0122336.	2.5	38
369	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). American Heart Journal, 2015, 170, 298-305.	2.7	38
370	Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure. Hypertension, 2015, 65, 5-15.	2.7	27
371	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the <scp>GISSIâ€HF</scp> and Valâ€ <scp>HeFT</scp> trials. European Journal of Heart Failure, 2015, 17, 424-433.	7.1	104
372	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	1.6	37
373	Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends in Endocrinology and Metabolism, 2015, 26, 201-211.	7.1	27
374	Population Risk Prediction Models for Incident Heart Failure. Circulation: Heart Failure, 2015, 8, 438-447.	3.9	69
375	Neutrophil Gelatinase–Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. Hypertension, 2015, 66, 158-166.	2.7	75
376	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the Highâ€Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 2015, 17, 1144-1151.	7.1	84
377	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the <scp>ASTRONAUT</scp> trial. European Journal of Heart Failure, 2015, 17, 98-108.	7.1	30
378	Regional Differences in Heart Failure With Preserved Ejection Fraction Trials. Circulation, 2015, 131, 7-10.	1.6	27

#	Article	IF	CITATIONS
379	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 709-716.	3.9	9
380	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. American Journal of Cardiology, 2015, 116, 1304-1310.	1.6	5
381	Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension, 2015, 66, 767-775.	2.7	129
382	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. European Journal of Heart Failure, 2015, 17, 135-143.	7.1	21
383	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal, 2015, 36, 2310-2317.	2.2	30
384	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure, 2015, 17, 224-232.	7.1	74
385	efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <scp>COMMANDER HF</scp> trial. European Journal of Heart	7.1	73
386	Patient, 2013, 17, 735-742. Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. Journal of the American College of Cardiology, 2015, 65, 1668-1682.	2.8	116
387	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. Molecular and Cellular Endocrinology, 2015, 411, 20-27.	3.2	26
388	Early and Late Effects of High- Versus Low-Dose Angiotensin Receptor Blockade on RenalÂFunction and Outcomes in Patients With Chronic Heart Failure. JACC: Heart Failure, 2015, 3, 214-223.	4.1	17
389	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	13.7	659
390	Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology, 2015, 192, 72-81.	1.7	28
391	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	1.7	635
392	Prognostic Value of Estimated PlasmaÂVolume in Heart Failure. JACC: Heart Failure, 2015, 3, 886-893.	4.1	101
393	To the Editor— Diabetes and sudden death: Let's assess the absolute risk increase rather than the proportional risk from sudden cardiac death!. Heart Rhythm, 2015, 12, e138.	0.7	2
394	Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. New England Journal of Medicine, 2015, 373, 1095-1105.	27.0	897
395	EXAMINE: targeting risk and treatment in diabetes $\hat{a} \in Authors'$ reply. Lancet, The, 2015, 386, 1445.	13.7	1
396	Long Term Safety and Efficacy Results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) Trial. Journal of Cardiac Failure, 2015, 21, 936.	1.7	2

#	Article	IF	CITATIONS
397	The Impact of Galectin-3 Inhibition onÂAldosterone-Induced Cardiac and RenalÂInjuries. JACC: Heart Failure, 2015, 3, 59-67.	4.1	164
398	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. European Heart Journal, 2015, 36, 425-433.	2.2	291
399	Sleep-disordered Breathing in Heart Failure – Current State of the Art. Cardiac Failure Review, 2015, 1, 16.	3.0	4
400	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thrombosis and Haemostasis, 2014, 111, 1141-1152.	3.4	26
401	Simultaneous Characterization of Metabolic, Cardiac, Vascular and Renal Phenotypes of Lean and Obese SHHF Rats. PLoS ONE, 2014, 9, e96452.	2.5	11
402	Effect of eplerenone in percutaneous coronary interventionâ€ŧreated postâ€myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the <scp>EPHESUS</scp> trial. European Journal of Heart Failure, 2014, 16, 685-691.	7.1	11
403	Opposite Predictive Value of Pulse Pressure and Aortic Pulse Wave Velocity on Heart Failure With Reduced Left Ventricular Ejection Fraction. Hypertension, 2014, 63, 105-111.	2.7	82
404	What Is Measured by Cardiac Fibrosis Biomarkers and Imaging?. Circulation: Heart Failure, 2014, 7, 239-242.	3.9	12
405	Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart, 2014, 100, 1681-1687.	2.9	26
406	Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study. European Journal of Heart Failure, 2014, 16, 526-534.	7.1	18
407	Trials of implantable monitoring devices in heart failure: which design is optimal?. Nature Reviews Cardiology, 2014, 11, 576-585.	13.7	31
408	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rateâ€lowering properties. European Journal of Heart Failure, 2014, 16, 76-85.	7.1	70
409	High prevalence of iron deficiency in patients with acute decompensated heart failure. European Journal of Heart Failure, 2014, 16, 984-991.	7.1	113
410	Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. International Journal of Cardiology, 2014, 177, 731-733.	1.7	19
411	Rationale and study design of the <scp>NEuroCardiac TherApy foR</scp> Heart Failure Study: <scp>NECTARâ€HF</scp> . European Journal of Heart Failure, 2014, 16, 692-699.	7.1	56
412	Noncardiac Comorbidities in HeartÂFailureÂWith Reduced Versus PreservedÂEjection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	2.8	424
413	Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. European Journal of Heart Failure, 2014, 16, 143-150.	7.1	25
414	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 2014, 23, 3-16.	1.5	565

#	Article	IF	CITATIONS
415	The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure, 2014, 16, 289-299.	7.1	19
416	Features of Cardiac Remodeling, Associated With Blood Pressure and Fibrosis Biomarkers, Are Frequent in Subjects With Abdominal Obesity. Hypertension, 2014, 63, 740-746.	2.7	57
417	Home Blood Pressure Monitoring: A Few minutes of Rest Before Measurement May Not Be Appropriate. American Journal of Hypertension, 2014, 27, 932-938.	2.0	7
418	Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist. Circulation: Heart Failure, 2014, 7, 573-579.	3.9	155
419	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology, 2014, 63, 853-871.	2.8	102
420	Heart failure with systolic dysfunction complicating acute myocardial infarction–Âdifferential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial. Archives of Cardiovascular Diseases, 2014, 107, 149-157.	1.6	9
421	Decongestion in acute heart failure. European Journal of Heart Failure, 2014, 16, 471-482.	7.1	113
422	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 () OirgBT /C)værdock 10 T
423	Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy. Circulation: Heart Failure, 2014, 7, 51-58.	3.9	203
424	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014, 35, 2295-2302.	2.2	128
425	Preface. Heart Failure Clinics, 2014, 10, xi.	2.1	1
426	Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488.	4.1	81
427	Current challenges for clinical trials of cardiovascular medical devices. International Journal of Cardiology, 2014, 175, 30-37.	1.7	37
428	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 260-268.	4.1	104
429	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	3.9	48
430	Telemedicine: What Framework, What Levels of Proof, Implementation Rules. Therapie, 2014, 69, 347-354.	1.0	2
431	Heart â€~omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	1.6	24
432	Loop diuretics and ultrafiltration in heart failure. Expert Opinion on Pharmacotherapy, 2013, 14, 1641-1648.	1.8	9

#	Article	IF	CITATIONS
433	Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology, 2013, 168, 1094-1101.	1.7	44
434	Effectiveness of a multidimensional home nurse led heart failure disease management program—A French nationwide time-series comparison. International Journal of Cardiology, 2013, 168, 3652-3658.	1.7	30
435	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	27.0	2,261
436	Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. Journal of the American College of Cardiology, 2013, 62, 1585-1593.	2.8	204
437	Learning from recent trials and shaping the future of acute heart failure trials. American Heart Journal, 2013, 166, 629-635.	2.7	30
438	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. European Journal of Heart Failure, 2013, 15, 61-68.	7.1	21
439	The past, present and future of renin–angiotensin aldosterone system inhibition. International Journal of Cardiology, 2013, 167, 1677-1687.	1.7	97
440	Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 67-75.	2.4	312
441	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 553-554.	0.2	4
442	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. International Journal of Cardiology, 2013, 167, 1772-1782.	1.7	67
443	Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. International Journal of Cardiology, 2013, 166, 729-735.	1.7	32
444	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure, 2013, 1, 488-496.	4.1	58
445	Clinical usefulness of an assay for measurement of circulating N-terminal pro-B-type natriuretic peptide concentration in dogs and cats with heart disease. Journal of the American Veterinary Medical Association, 2013, 243, 71-82.	0.5	49
446	Continuous Positive Airway Pressure (CPAP) May Not Reduce Short-Term Mortality in Cardiogenic Pulmonary Edema: A Propensity-Based Analysis. Journal of Cardiac Failure, 2013, 19, 108-116.	1.7	8
447	SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL. Journal of the American College of Cardiology, 2013, 61, E631.	2.8	0
448	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. Journal of the American College of Cardiology, 2013, 61, 571-579.	2.8	58
449	Relationship between catalase haplotype and arterial aging. Atherosclerosis, 2013, 227, 100-105.	0.8	14
450	Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (from the EVEREST Trial). American Journal of Cardiology, 2013, 112, 1763-1769.	1.6	8

#	Article	IF	CITATIONS
451	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	3.9	28
452	Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. European Heart Journal, 2013, 34, 2271-2280.	2.2	63
453	Clinical Course of Patients With Hyponatremia andÂDecompensated Systolic Heart Failure and the Effect ofÂVasopressin Receptor Antagonism With Tolvaptan. Journal of Cardiac Failure, 2013, 19, 390-397.	1.7	130
454	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1125.	7.4	297
455	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,681
456	Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. European Journal of Heart Failure, 2013, 15, 221-227.	7.1	10
457	Prognostic value of serum <scp>PIIINP</scp> , <scp> MMP</scp> 1 and <scp>TIMP</scp> 1 levels in hypertensive patients: a communityâ€based prospective cohort study. Fundamental and Clinical Pharmacology, 2013, 27, 572-580.	1.9	20
458	Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. European Heart Journal, 2013, 34, 835-843.	2.2	418
459	International differences in treatment effect: do they really exist and why?â€. European Heart Journal, 2013, 34, 1846-1852.	2.2	53
460	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	2.2	53
461	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal, 2013, 34, 2453-2463.	2.2	419
462	Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study. American Journal of Nephrology, 2013, 37, 144-151.	3.1	29
463	Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy. Circulation: Heart Failure, 2013, 6, 711-718.	3.9	35
464	Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure. Circulation: Heart Failure, 2013, 6, 970-976.	3.9	33
465	Extracellular Matrix Turnover Biomarkers Predict Long-Term Left Ventricular Remodeling After Myocardial Infarction. Circulation: Heart Failure, 2013, 6, 1199-1205.	3.9	34
466	Soluble ST2 in Ambulatory Patients With Heart Failure. Circulation: Heart Failure, 2013, 6, 1172-1179.	3.9	114
467	Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases. Current Opinion in Nephrology and Hypertension, 2013, 22, 59-64.	2.0	24
468	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. European Heart Journal, 2013, 34, 2823-2829.	2.2	79

#	Article	IF	CITATIONS
469	Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice. Hypertension, 2013, 61, 120-129.	2.7	42
470	Serum aldosterone is associated with mortality and reâ€hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. European Journal of Heart Failure, 2013, 15, 1228-1235.	7.1	51
471	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
472	Rationale and design of the SERVEâ€HF study: treatment of sleepâ€disordered breathing with predominant central sleep apnoea with adaptive servoâ€ventilation in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 937-943.	7.1	106
473	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094.	7.1	182
474	Association between diabetes mellitus and postâ€discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. European Journal of Heart Failure, 2013, 15, 194-202.	7.1	155
475	EUR <i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	7.1	645
476	Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. European Journal of Heart Failure, 2013, 15, 1382-1389.	7.1	21
477	Gene Expression Profile of Blood Cells for the Prediction of Delayed Cerebral Ischemia after Intracranial Aneurysm Rupture: A Pilot Study in Humans. Cerebrovascular Diseases, 2013, 36, 236-242.	1.7	9
478	Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2013, 6, 47-52.	3.9	61
479	A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats. PLoS ONE, 2013, 8, e79176.	2.5	37
480	The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis. PLoS ONE, 2013, 8, e71659.	2.5	44
481	Predicting Maximal HR in Heart Failure Patients on β-Blockade Therapy. Medicine and Science in Sports and Exercise, 2012, 44, 371-376.	0.4	36
482	Eplerenone: is it time to add this drug to current heart failure therapy?. Therapeutic Advances in Chronic Disease, 2012, 3, 5-9.	2.5	6
483	Neutrophil Gelatinase-Associated Lipocalin Is a Novel Mineralocorticoid Target in the Cardiovascular System. Hypertension, 2012, 59, 966-972.	2.7	73
484	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,233
485	Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction. Circulation, 2012, 125, 271-279.	1.6	136
486	Galectin-3 in Ambulatory Patients With Heart Failure. Circulation: Heart Failure, 2012, 5, 72-78.	3.9	211

#	Article	IF	CITATIONS
487	Visit-to-Visit Blood Pressure Variability Is a Strong Predictor of Cardiovascular Events in Hemodialysis. Hypertension, 2012, 60, 339-346.	2.7	92
488	Rationale and design of ARTS: a randomized, doubleâ€blind study of BAY 94â€8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure, 2012, 14, 668-675.	7.1	72
489	Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. European Journal of Heart Failure, 2012, 14, 302-311.	7.1	159
490	Factors Related to Morbidity and Mortality in Patients With Chronic Heart Failure With Systolic Dysfunction. Circulation: Heart Failure, 2012, 5, 63-71.	3.9	178
491	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795.	2.2	148
492	When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches. Circulation: Heart Failure, 2012, 5, 294-302.	3.9	23
493	Cardiotrophin 1 Is Involved in Cardiac, Vascular, and Renal Fibrosis and Dysfunction. Hypertension, 2012, 60, 563-573.	2.7	55
494	Risk-guided therapy: a first step to personalized medicine. European Journal of Preventive Cardiology, 2012, 19, 5-6.	1.8	8
495	Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. European Heart Journal, 2012, 33, 1049-1057.	2.2	19
496	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine, 2012, 13, 415-422.	1.5	29
497	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.8	414
498	Eplerenone and newâ€onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASISâ€HF). European Journal of Heart Failure, 2012, 14, 909-915.	7.1	59
499	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure, 2012, 14, 1401-1409.	7.1	25
500	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention	2.2	5,247
501	Association of galectinâ€3 and fibrosis markers with longâ€term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CAREâ€HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 2012, 14, 74-81.	7.1	203
502	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
503	Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Fundamental and Clinical Pharmacology, 2012, 26, 163-174.	1.9	32
504	Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms. Circulation, 2012, 126, 2317-2323.	1.6	90

#	Article	IF	CITATIONS
505	Hypo- and Hyperglycemia Predict Outcome in Patients With Left Ventricular Dysfunction After Acute Myocardial Infarction: Data From EPHESUS. Journal of Cardiac Failure, 2012, 18, 439-445.	1.7	34
506	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. Journal of Cardiac Failure, 2012, 18, 515-523.	1.7	62
507	Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 750-758.	3.9	89
508	Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure. Journal of the American College of Cardiology, 2012, 60, 2082-2089.	2.8	218
509	Implications of geographical variation on clinical outcomes of cardiovascular trials. American Heart Journal, 2012, 164, 303-312.	2.7	44
510	Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1598-1603.	2.8	249
511	Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2012, 110, 1657-1662.	1.6	14
512	Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 0 0 rgB1	-/ 0.v erlock	2 160 Tf 50 45
513	The Detection of Myocardial Fibrosis. Circulation: Cardiovascular Imaging, 2012, 5, 9-11.	2.6	17
514	Can we prevent or treat renal dysfunction in chronic heart failure?. Heart Failure Reviews, 2012, 17, 283-290.	3.9	8
515	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90Âdays: analysis from the EVEREST trial. Heart Failure Reviews, 2012, 17, 485-509.	3.9	100
516	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. European Journal of Heart Failure, 2011, 13, 1253-1260.	7.1	32
517	Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects. Journal of the American College of Cardiology, 2011, 58, 1958-1966.	2.8	117
518	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	27.0	2,491
519	Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials. American Heart Journal, 2011, 161, 1067-1072.	2.7	37
520	The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. International Journal of Cardiology, 2011, 150, 277-282.	1.7	40
521	Surrogate endpoints in randomized cardiovascular clinical trials. Fundamental and Clinical Pharmacology, 2011, 25, 411-413.	1.9	14

522Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac
Insufficiency Bisoprolol Survival Study (CIBIS-II). Cardiovascular Drugs and Therapy, 2011, 25, 77-85.2.612

#	Article	IF	CITATIONS
523	Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD Study. Nephrology Dialysis Transplantation, 2011, 26, 2891-2898.	0.7	25
524	Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. European Heart Journal, 2011, 32, 820-828.	2.2	359
525	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. European Heart Journal, 2011, 32, 2563-2572.	2.2	116
526	Rationale and design of the multicentre, randomized, doubleâ€blind, placebo ontrolled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure, 2011, 13, 100-106.	7.1	68
527	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	7.1	350
528	Rosuvastatin in Diabetic Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2011, 22, 1335-1341.	6.1	105
529	Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 389-398.	2.2	111
530	Effect of two oral doses of 17βâ€estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized doubleâ€blind placeboâ€controlled study. Fundamental and Clinical Pharmacology, 2010, 24, 239-245.	1.9	1
531	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325.	3.9	134
532	Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction. American Journal of Therapeutics, 2010, 17, e78-e87.	0.9	17
533	Extracellular matrix fibrotic markers in heart failure. Heart Failure Reviews, 2010, 15, 319-329.	3.9	85
534	Editorial: Sudden cardiac death – the challenge to cardiology. Fundamental and Clinical Pharmacology, 2010, 24, 535-537.	1.9	2
535	Association Study of Gene Polymorphisms Involved in Vascular Alterations in Elderly Hypertensives with Subjective Memory Complaints. Dementia and Geriatric Cognitive Disorders, 2010, 30, 440-448.	1.5	11
536	EUR <i>Observational</i> Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	7.1	340
537	Critical elements of clinical followâ€up after hospital discharge for heart failure: insights from the EVEREST trial. European Journal of Heart Failure, 2010, 12, 367-374.	7.1	78
538	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBISâ€II) trial. European Journal of Heart Failure, 2010, 12, 607-616.	7.1	71
539	Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal, 2010, 31, 2205-2208.	2.2	31
540	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433.	7.1	593

#	Article	IF	CITATIONS
541	Left bundle branch block and mortality in patients with acute heart failure syndrome: a substudy of the EFICA cohort. European Journal of Heart Failure, 2010, 12, 156-163.	7.1	33
542	Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: A propensity-matched study of the EPHESUS trial. International Journal of Cardiology, 2010, 143, 309-316.	1.7	18
543	Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure, 2010, 16, S73-S74.	1.7	0
544	Maximizing scientific knowledge from randomized clinical trials. American Heart Journal, 2010, 159, 937-943.	2.7	12
545	Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASISâ€HF). European Journal of Heart Failure, 2010, 12, 617-622.	7.1	66
546	Heart Failure Pilot protocol. European Heart Journal, 2010, 31, 2184-6.	2.2	2
547	Cardiovascular disease in patients with renal disease: the role of statins. Current Medical Research and Opinion, 2009, 25, 271-285.	1.9	34
548	Vascular Structure and Function Is Correlated to Cognitive Performance and White Matter Hyperintensities in Older Hypertensive Patients With Subjective Memory Complaints. Stroke, 2009, 40, 1229-1236.	2.0	231
549	Pulse Wave Velocity Assessment by External Noninvasive Devices and Phase-Contrast Magnetic Resonance Imaging in the Obese. Hypertension, 2009, 54, 421-426.	2.7	97
550	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 119-129.	7.1	281
551	Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. European Heart Journal, 2009, 30, 1666-1673.	2.2	68
552	Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure. Circulation, 2009, 119, 2471-2479.	1.6	241
553	Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1439.	7.4	1,694
554	Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial. American Journal of Cardiology, 2009, 103, 82-87.	1.6	76
555	Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trialâ€. European Journal of Heart Failure, 2009, 11, 1099-1105.	7.1	73
556	Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?. Journal of Cardiac Failure, 2009, 15, 199-205.	1.7	27
557	Low serum magnesium and cardiovascular mortality in chronic heart failure: A propensity-matched study. International Journal of Cardiology, 2009, 136, 270-277.	1.7	65
558	N-terminal pro–brain natriuretic peptide and exercise capacity in chronic heart failure: Data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. American Heart Journal, 2009, 158, S37-S44.	2.7	31

#	Article	IF	CITATIONS
559	Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging, 2009, 2, 187-198.	5.3	59
560	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 360, 1395-1407.	27.0	1,781
561	Biomarkers of Extracellular Matrix Turnover. Heart Failure Clinics, 2009, 5, 589-599.	2.1	7
562	Effects of tolvaptan on dyspnoea relief from the EVEREST trials. European Heart Journal, 2009, 30, 2233-2240.	2.2	71
563	Response to Letter by Hnid. Stroke, 2009, 40, .	2.0	0
564	C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes. Thrombosis and Haemostasis, 2008, 99, 558-569.	3.4	58
565	Sympathetic-leptin relationship in obesity: effect of weight loss. Metabolism: Clinical and Experimental, 2008, 57, 555-562.	3.4	37
566	Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1640-1648.	2.8	159
567	Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. Journal of the American College of Cardiology, 2008, 52, 2017-2028.	2.8	138
568	A propensity matched study of the association of education and outcomes in chronic heart failure. International Journal of Cardiology, 2008, 129, 93-99.	1.7	39
569	Incident Heart Failure Hospitalization and Subsequent Mortality in Chronic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure, 2008, 14, 211-218.	1.7	139
570	Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. Journal of Cardiac Failure, 2008, 14, 467-474.	1.7	79
571	Correlation of Ejection Fraction to Early Post-Discharge Sudden Death and All-Cause Mortality in The EVEREST Trial. Journal of Cardiac Failure, 2008, 14, S70-S71.	1.7	0
572	C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis, 2008, 200, 286-293.	0.8	37
573	Clinical Implications of QRS Duration in Patients Hospitalized With Worsening Heart Failure and Reduced Left Ventricular Ejection Fraction. JAMA - Journal of the American Medical Association, 2008, 299, 2656.	7.4	168
574	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal, 2008, 29, 748-756.	2.2	102
575	Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. European Heart Journal, 2008, 29, 1739-1752.	2.2	90
576	Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure, 2008, 10, 201-213.	7.1	39

#	Article	IF	CITATIONS
577	Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. European Heart Journal, 2008, 29, 413-421.	2.2	41
578	Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure, 2008, 10, 1229-1235.	7.1	29
579	History of Hypertension and Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure. Hypertension, 2008, 52, 271-278.	2.7	22
580	State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure, 2008, 10, 824-839.	7.1	691
581	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Critical Care Medicine, 2008, 36, S129-S139.	0.9	240
582	Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. European Journal of Heart Failure, 2007, 9, 370-376.	7.1	10
583	Ejection fraction and blood pressure are important and interactive predictors of 4â€week mortality in severe acute heart failure. European Journal of Heart Failure, 2007, 9, 935-941.	7.1	32
584	Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace, 2007, 9, 724-729.	1.7	68
585	A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. European Heart Journal, 2007, 28, 1334-1343.	2.2	166
586	Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. European Heart Journal, 2007, 28, 1904-1909.	2.2	24
587	Left bundle branch block as a risk factor for progression to heart failure. European Journal of Heart Failure, 2007, 9, 7-14.	7.1	142
588	Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure <subtitle>The EVEREST Outcome Trial</subtitle> . JAMA - Journal of the American Medical Association, 2007, 297, 1319.	7.4	1,406
589	Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure <subtitle>The EVEREST Clinical Status Trials</subtitle> . JAMA - Journal of the American Medical Association, 2007, 297, 1332.	7.4	757
590	Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study. Kidney and Blood Pressure Research, 2007, 30, 314-322.	2.0	56
591	Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrology Dialysis Transplantation, 2007, 22, 3573-3579.	0.7	41
592	Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI) Trial. Journal of Clinical Hypertension, 2007, 9, 120-127.	2.0	11
593	Globalization of cardiovascular clinical research: The balance between meeting medical needs and maintaining scientific standards. American Heart Journal, 2007, 154, 232-238.	2.7	43
594	Regional Differences in Baseline Characteristics and Outcomes in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction. Journal of Cardiac Failure, 2007, 13, S77.	1.7	0

#	Article	IF	CITATIONS
595	Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundamental and Clinical Pharmacology, 2007, 21, 181-190.	1.9	30
596	Haemorheological disturbances in hypertensive type 2 diabetic patients – influence of antihypertensive therapy. Fundamental and Clinical Pharmacology, 2007, 21, 387-396.	1.9	16
597	FCP welcomes Cardiovascular Pharmacology and Drug Therapy. Fundamental and Clinical Pharmacology, 2007, 21, 457-457.	1.9	0
598	Effects of Valsartan Alone Versus Valsartan/Simvastatin Combination on Ambulatory Blood Pressure, C-Reactive Protein, Lipoproteins, and Monocyte Chemoattractant Protein–1 in Patients With Hyperlipidemia and Hypertension. American Journal of Cardiology, 2007, 100, 222-226.	1.6	29
599	An introduction to acute heart failure syndromes: definition and classification. Heart Failure Reviews, 2007, 12, 87-90.	3.9	61
600	Epidemiology of acute heart failure syndromes. Heart Failure Reviews, 2007, 12, 91-95.	3.9	124
601	Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA studyâ †. European Journal of Heart Failure, 2006, 8, 697-705.	7.1	286
602	The challenge of acute decompensated heart failure. Heart Failure Reviews, 2006, 11, 135-139.	3.9	29
603	Early changes in serum markers of cardiac extraâ€cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. European Journal of Heart Failure, 2006, 8, 147-153.	7.1	62
604	Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionâ~†. European Journal of Heart Failure, 2006, 8, 591-598.	7.1	111
605	Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction â‰ 8 0%. European Journal of Heart Failure, 2006, 8, 295-301.	7.1	38
606	Benefits, challenges, and registerability of the polypill. European Heart Journal, 2006, 27, 1651-1656.	2.2	88
607	Initial infarct size predicts subsequent cardiac remodeling in the rat infarct model: an in vivo serial pinhole gated SPECT study. Journal of Nuclear Medicine, 2006, 47, 337-44.	5.0	19
608	Metabolic Syndrome, New Onset Diabetes, and New End points in Cardiovascular Trials. Journal of Cardiovascular Pharmacology, 2006, 47, 469-475.	1.9	30
609	Changes in First-Pass Interstitial Kinetics of DTPA in Myocardium Submitted to Low-Flow Ischemia. Investigative Radiology, 2005, 40, 766-772.	6.2	4
610	Anaphylactic Shock. Anesthesiology, 2005, 103, 40-49.	2.5	62
611	High-resolution simultaneous imaging of SPECT, PET, and MRI tracers on histologic sections of myocardial infarction. Journal of Nuclear Cardiology, 2005, 12, 229-230.	2.1	17
612	Effect of MR Blockade on Collagen Formation and Cardiovascular Disease with a Specific Emphasis on Heart Failure. Heart Failure Reviews, 2005, 10, 71-78.	3.9	70

#	Article	IF	CITATIONS
613	Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure, 2005, 14, 196-209.	1.5	67
614	Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. Circulation, 2005, 112, 3391-3399.	1.6	101
615	Acute Heart Failure Syndromes. Circulation, 2005, 112, 3958-3968.	1.6	690
616	Public awareness of heart failure in Europe: first results from SHAPE. European Heart Journal, 2005, 26, 2413-2421.	2.2	118
617	Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression. Molecular and Cellular Endocrinology, 2005, 245, 67-76.	3.2	29
618	Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure, 2005, 11, 260-269.	1.7	168
619	New Insights into RAAS Inhibition in Heart Failure. Journal of Cardiac Failure, 2005, 11, S239-S240.	1.7	0
620	Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. Journal of the American College of Cardiology, 2005, 46, 425-431.	2.8	350
621	Impaired response of cardiac autonomic nervous system to glucose load in severe obesity. Metabolism: Clinical and Experimental, 2005, 54, 966-974.	3.4	13
622	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. Circulation, 2004, 109, 1594-1602.	1.6	1,062
623	Rationale, design and methods of the CASHMERE study+. Fundamental and Clinical Pharmacology, 2004, 18, 131-138.	1.9	19
624	Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol. Fundamental and Clinical Pharmacology, 2004, 18, 483-491.	1.9	9
625	Increasing Awareness and Perception of Heart Failure in Europe and Improving Care—Rationale and Design of the SHAPE Study. Cardiovascular Drugs and Therapy, 2004, 18, 153-159.	2.6	14
626	Compared efficacy of three currently recommended antihypertensive strategies in Europe. American Journal of Cardiovascular Drugs, 2004, 4, 13-14.	2.2	0
627	Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. Journal of the American College of Cardiology, 2004, 43, 353-359.	2.8	43
628	The effect of eplerenone on all-cause mortality and heart failure hospitalization in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Journal of Cardiac Failure, 2004, 10, S76.	1.7	1
629	Low-flow ischaemia has no deleterious effect on the steady-state kinetics of 201Tl and 99mTc sestamibi within myocardial tissue. Nuclear Medicine Communications, 2004, 25, 475-478.	1.1	2
630	The Results of Major Clinical Trials. Therapie, 2004, 59, 323-328.	1.0	0

#	Article	IF	CITATIONS
631	Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with β-blockers. Journal of Nuclear Cardiology, 2003, 10, 361-368.	2.1	19
632	Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. Journal of Evaluation in Clinical Practice, 2003, 9, 373-382.	1.8	12
633	Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 2003, 348, 1309-1321.	27.0	4,403
634	Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy. Circulation, 2003, 108, 1831-1838.	1.6	605
635	Genetics of intima-media thickness. Current Opinion in Lipidology, 2003, 14, 191-200.	2.7	25
636	Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure: Practice versus Guidelines. Journal of Pharmacy Technology, 2002, 18, 229-240.	1.0	2
637	Selfâ€rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. European Journal of Heart Failure, 2002, 4, 337-343.	7.1	141
638	Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. American Heart Journal, 2002, 144, 508-515.	2.7	66
639	FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundamental and Clinical Pharmacology, 2002, 16, 353-360.	1.9	16
640	Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril1. Fundamental and Clinical Pharmacology, 2002, 16, 545-554.	1.9	4
641	Retinoic Acid Attenuates Inducible Nitric Oxide Synthase (NOS2) Activation in Cultured Rat Cardiac Myocytes and Microvascular Endothelial Cells. Journal of Molecular and Cellular Cardiology, 2001, 33, 933-945.	1.9	27
642	Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST. American Heart Journal, 2001, 141, 908-914.	2.7	32
643	The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE Study. American Journal of Hypertension, 2001, 14, 1083-1089.	2.0	43
644	Antihypertensive drugs. Side Effects of Drugs Annual, 2001, 24, 233-245.	0.6	0
645	Retinoic Acid and Lipopolysaccharide Act Synergistically to Increase Prostanoid Concentrations in Rats In Vivo. Journal of Nutrition, 2001, 131, 2628-2635.	2.9	16
646	Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin-resistance. Clinical Autonomic Research, 2001, 11, 79-86.	2.5	36
647	Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. British Journal of Clinical Pharmacology, 2001, 52, 687-692.	2.4	7
648	The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovascular Drugs and Therapy, 2001, 15, 79-87.	2.6	306

#	Article	IF	CITATIONS
649	Treatment of Congestive Heart Failure. Hypertension, 2001, 38, 1227-1232.	2.7	125
650	Lipopolysaccharide-Induced Increase of Prostaglandin E2 Is Mediated by Inducible Nitric Oxide Synthase Activation of the Constitutive Cyclooxygenase and Induction of Membrane-Associated Prostaglandin E Synthase. Journal of Immunology, 2001, 167, 3962-3971.	0.8	55
651	Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension. Blood Pressure, 2000, 9, 36-39.	1.5	7
652	Differential clinical prognostic classifications in dilated and ischemic adbanced heart failure: The EPICAL study. American Heart Journal, 2000, 139, 895-904.	2.7	77
653	Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Human Genetics, 2000, 107, 58-61.	3.8	16
654	Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure. Circulation, 2000, 102, 2700-2706.	1.6	878
655	Antihypertensive drugs. Side Effects of Drugs Annual, 2000, 23, 217-224.	0.6	0
656	The Potential Advantages of a Modern Antihypertensive Therapy in the Elderly. Journal of Cardiovascular Pharmacology, 2000, 35, S19-S23.	1.9	10
657	Effets des inhibiteurs calciques sur la progression de l??ath??roscl??rose et de l????paisseur intima m??dia. Drugs, 2000, 59, 39-46.	10.9	5
658	The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 1999, 341, 709-717.	27.0	8,093
659	Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. Journal of the American College of Cardiology, 1999, 33, 734-742.	2.8	276
660	Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). American Heart Journal, 1999, 138, 78-86.	2.7	462
661	Antihypertensive drugs. Side Effects of Drugs Annual, 1999, 22, 224-232.	0.6	0
662	Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. European Journal of Heart Failure, 1999, 1, 81-88.	7.1	14
663	Over 20 years' experience of β-blockade in heart failure. Progress in Cardiovascular Diseases, 1998, 41, 31-37.	3.1	7
664	Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. American Heart Journal, 1998, 136, 672-680.	2.7	16
665	Clinical definition and epidemiology of advanced heart failure. American Heart Journal, 1998, 135, S204-S215.	2.7	141
666	Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis, 1998, 140, 89-95.	0.8	51

#	Article	IF	CITATIONS
667	Antihypertensive drugs. Side Effects of Drugs Annual, 1997, 20, 194-199.	0.6	0
668	A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). American Heart Journal, 1997, 134, 44-54.	2.7	648
669	Effects of Blood Pressure Control on Radial Artery Diameter and Compliance in Hypertensive Patients. American Journal of Hypertension, 1997, 10, 269-274.	2.0	17
670	Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. American Heart Journal, 1996, 131, 560-566.	2.7	52
671	Investigations of the peripheral vascular mechanisms implicated in congestive heart failure by the non-invasive evaluation of radial artery compliance and reactivity. International Journal of Cardiology, 1996, 56, 149-158.	1.7	18
672	Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. Clinical Therapeutics, 1996, 18, 726-746.	2.5	22
673	Plasma levels of atrial natriuretic peptide and of other vasoconstricting hormones in patients with chronic heart failure: relationship to exercise capacity. International Journal of Cardiology, 1996, 57, 135-142.	1.7	5
674	Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clinical Genetics, 1996, 50, 339-347.	2.0	26
675	Antihypertensive drugs. Side Effects of Drugs Annual, 1995, 19, 209-217.	0.6	0
676	Duration of Action of Angiotensin Converting Enzyme Inhibitors. American Journal of Hypertension, 1995, 8, 75S-81S.	2.0	16
677	Contribution of specific skeletal muscle metabolic abnormalities to limitation of exercise capacity in patients with chronic heart failure: A phosphorus 31 nuclear magnetic resonance study. American Heart Journal, 1994, 128, 781-792.	2.7	37
678	Antihypertensive drugs. Side Effects of Drugs Annual, 1994, 18, 222-227.	0.6	0
679	Calcium Antagonists in Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1990, 16, S16-S19.	1.9	0
680	Effect of diltiazem on myocardial infarct size estimated by enzyme release, serial thallium-201 single-photon emission computed tomography and radionuclide angiography. American Journal of Cardiology, 1988, 61, 1172-1177.	1.6	22
681	Clinical research in Africa And Middle East: Roadmap for reform and harmonisation of the regulatory framework and sustainable capacity development. Journal of Global Health Reports, 0, 3, .	1.0	6